Previous Article | Next Article ![]()
Infection and Immunity, January 2000, p. 93-99, Vol. 68, No. 1
Helminth Immunology Section, Laboratory of
Parasitic Diseases, National Institute of Allergy and Infectious
Diseases, National Institutes of Health, Bethesda, Maryland
20892,1 and Tuberculosis Research
Centre2 and Government General
Hospital,3 Madras, India
Received 11 June 1999/Returned for modification 6 August
1999/Accepted 6 October 1999
Treatment of patients with patent Wuchereria bancrofti
infection results in an acute clinical reaction and peripheral
eosinophilia. To investigate the dynamics of the eosinophil response,
changes in eosinophil activation and degranulation and plasma levels of eosinophil-active chemokines and cytokines were studied in 15 microfilaremic individuals in south India by sequential blood sampling
before and after administration of 300 mg of diethylcarbamazine (DEC).
Clinical symptoms occurred within 24 h. Plasma interleukin-5 (IL-5) and RANTES levels peaked 1 to 2 days posttreatment, preceding a
peak peripheral eosinophil count at day 4. Major basic protein secretion from eosinophils paralleled IL-5 secretion, while levels of
eosinophil-derived neurotoxin peaked at day 13 after treatment. Expression of the activation markers HLA-DR and CD25 on eosinophils rose markedly immediately after treatment, while expression of VLA-4
and
0019-9567/0/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Perturbations in Eosinophil Homeostasis following
Treatment of Lymphatic Filariasis
4
7 showed an early peak within 24 h and a second peak at
day 13. Thus, the posttreatment reactions seen in filarial infections
can be divided into an early phase with killing of microfilariae,
clinical symptomatology, increases in plasma IL-5 and RANTES levels,
and eosinophil activation and degranulation and a later phase with
expression of surface integrins on eosinophils, recruitment of
eosinophils from the bone marrow to tissues, and clearance of parasite antigen.
*
Corresponding author. Mailing address: LPD, NIAID,
Building 4, Room 126, NIH, Bethesda, MD 20892. Phone: (301) 496-3449. Fax: (301) 480-3757. E-mail: rgopinath{at}niaid.nih.gov.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»